Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(2):81; doi:10.1093/jnci/97.2.81
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

In This Issue

The first 10% of the full text of this article appears below.

Locoregional Radiation Therapy in High-Risk Breast Cancer

In the British Columbia randomized radiation therapy trial, premenopausal patients with lymph node-positive breast cancer treated by mastectomy and adjuvant chemotherapy were randomly assigned to no additional treatment or to receive locoregional radiation therapy. After 20 years of follow-up for this trial, Ragaz et al. (p. 116) report that radiation therapy and chemotherapy, compared with chemotherapy alone, was associated with a statistically significant improvement in all end points analyzed, including isolated locoregional recurrence, systemic relapse-free survival, disease-free survival, event-free survival, breast cancer death-free survival, and overall survival. In addition, long-term toxic effects, including . . . [Full Text of this Article]

DNA Repair and Breast Cancer Risk

Role of Human Cripto-1 in Tumor Angiogenesis

Increase in Esophageal Cancer Incidence

Designing SELECT

Epigenetic Changes in Prostate Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?